Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 août 2018 08h00 HE | Source: AVROBIO, Inc.

AVROBIO, Inc. to Present at the 2018 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative...
27 juin 2018 08h00 HE | Source: AVROBIO, Inc.

AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors

CAMBRIDGE, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical stage gene therapy company focused on developing potentially curative lentiviral-based gene...
25 juin 2018 16h30 HE | Source: AVROBIO, Inc.

AVROBIO, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Option

CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo...
20 juin 2018 20h42 HE | Source: AVROBIO, Inc.

AVROBIO, Inc. Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., June 20, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based...